SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway

Blood

Volumn 103, Issue 12, 2004, Pages 4630-4635

  Chim, Chor Sang ^a   Fung, Tsz Kin ^a   Cheung, Wai Chung ^a   Liang, Raymond ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL STRAIN; CELL STRAIN U 266; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE ACTIVATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 2942584857     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2007     Document Type: Article

References (43)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927-937.
3. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
4. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am. 1997;11:71-87.
5. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000;95:19-29.
6. O'Shea JJ, Gadina M, Schreiber RD. Cell. 2002;109(suppl):S121-S131.
7. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002;2:410-416.
8. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297-314.
9. Myers MP, Andersen JN, Cheng A, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem. 2001;276:47771-47774.
10. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921.
11. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
12. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-929.
13. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
14. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003;306:1-12.
15. Chim CS, Liang R, Kwong YL. Gene promoter hypermethylation in hematologic malignancies. Hematol Oncol. 2002;20:167-176.
16. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev. 2000;1:11-19.
17. Singal R, Ginder GD. DNA methylation. Blood. 1999;93:4059-4070.
18. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-5440.
19. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-167.
20. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H. A methylation suppresses transcription in vivo. Nat Genet. 1999;22:23-26.
21. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
22. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29-35.
23. Nagai H, Naka T, Terada Y, et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet. 2003;48:65-69.
24. Salmon S, Cassady JR. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg S, eds. Cancer, Principles and Practice of Oncology. Philadelphia, PA: JB Lippincott; 1997:2344-2387.
25. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
27. Chim CS, Liang R, Tam C, Kwong YL. P15 and P16 promoter methylation in acute promyelocytic leukemia. J Clin Oncol. 2001;19:2033-2040.
28. Chim CS, Tam C, Liang R, Kwong YL. P15 and P16 gene methylation in adult acute leukemia: lack of prognostic significance. Cancer. 2001;91:2222-2229.
29. Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390-6394.
30. Banville, D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 1995;27:165-173.
31. Chim CS, Wong SY, Kwong YL. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol. 2003;122:571-578.
32. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem. 1997;272:22322-22329.
33. Melki JR, Vincent PC, Clark SJ. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia. 1999;13:877-883.
34. Nicholson SE, Willson TA, Farley A, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999;18:375-385.
35. Yasukawa H, Misawa H, Sakamoto H, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 1999;18:1309-1320.
36. Rottapel R, Ilangumaran S, Neale C, et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002;21:4351-4362.
37. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003;101:2784-2788.
38. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 2000;157:1137-1146.
39. Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol. 2003;162:1449-1461.
40. He J, Olson JJ, James CD. Lack of p161NK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 1995;55:4833-4836.
41. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 1996;56:5475-5483.
42. Shapiro GI, Park JE, Edwards CD, et al. Multiple mechanisms of p161NK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 1995;55:6200-6209.
43. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs. retinoblastoma inactivation: inmplications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A. 1994;91:7827-7831.